ATE211171T1 - Weitgehend reine rezeptorartige, tgf-beta-1- bindende moleküle und deren verwendungen - Google Patents

Weitgehend reine rezeptorartige, tgf-beta-1- bindende moleküle und deren verwendungen

Info

Publication number
ATE211171T1
ATE211171T1 AT92914515T AT92914515T ATE211171T1 AT E211171 T1 ATE211171 T1 AT E211171T1 AT 92914515 T AT92914515 T AT 92914515T AT 92914515 T AT92914515 T AT 92914515T AT E211171 T1 ATE211171 T1 AT E211171T1
Authority
AT
Austria
Prior art keywords
beta
tgf
pct
molecules
type
Prior art date
Application number
AT92914515T
Other languages
English (en)
Inventor
Hidenori Ichijo
Kohei Miyazono
Lars Roennstrand
Ulf Hellman
Christer Wernstedt
Carl-Henrik Heldin
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE211171T1 publication Critical patent/ATE211171T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT92914515T 1991-06-18 1992-06-18 Weitgehend reine rezeptorartige, tgf-beta-1- bindende moleküle und deren verwendungen ATE211171T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/717,316 US5229495A (en) 1991-06-18 1991-06-18 Substantially pure receptor like TGF-β 1 binding molecules and uses thereof
PCT/US1992/005199 WO1992022319A1 (en) 1991-06-18 1992-06-18 SUBSTANTIALLY PURE RECEPTOR LIKE TGF-β1 BINDING MOLECULES AND USES THEREOF

Publications (1)

Publication Number Publication Date
ATE211171T1 true ATE211171T1 (de) 2002-01-15

Family

ID=24881526

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92914515T ATE211171T1 (de) 1991-06-18 1992-06-18 Weitgehend reine rezeptorartige, tgf-beta-1- bindende moleküle und deren verwendungen

Country Status (10)

Country Link
US (3) US5229495A (de)
EP (1) EP0590071B1 (de)
JP (1) JPH06508519A (de)
AT (1) ATE211171T1 (de)
AU (1) AU665561B2 (de)
CA (1) CA2111853C (de)
DE (2) DE69232309D1 (de)
DK (1) DK0590071T3 (de)
ES (1) ES2165843T3 (de)
WO (1) WO1992022319A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150328A (en) * 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
US5705609A (en) * 1988-06-28 1998-01-06 La Jolla Cancer Research Foundation Decorin fragments inhibiting cell regulatory factors
US5177197A (en) * 1990-02-27 1993-01-05 Ludwig Institute For Cancer Research Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
US5229495A (en) * 1991-06-18 1993-07-20 Ludwig Institute For Cancer Research Substantially pure receptor like TGF-β 1 binding molecules and uses thereof
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6008011A (en) * 1991-10-31 1999-12-28 Whitehead Institute For Biomedical Research TGF-β type II receptor cDNAs
US20080139474A1 (en) * 1991-11-04 2008-06-12 David Israel Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
DE69233022T2 (de) * 1991-11-04 2004-02-12 Genetics Institute, LLC, Cambridge Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) * 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US5981568A (en) * 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
WO1994026303A1 (en) * 1993-05-13 1994-11-24 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US5453492A (en) * 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
DE69434651T2 (de) 1993-12-07 2007-03-08 Genetics Institute, Inc., Cambridge Bmp-12, bmp-13 und diese enthaltende sehne-induzierende zusammensetzungen
US6074840A (en) 1994-02-18 2000-06-13 The Regents Of The University Of Michigan Recombinant production of latent TGF-beta binding protein-3 (LTBP-3)
JPH11510479A (ja) 1995-06-07 1999-09-14 ネオルックス コーポレイション タモキシフェン類似体による心臓血管疾病の予防及び治療
WO1998046588A2 (en) * 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
US6444657B1 (en) 1998-12-31 2002-09-03 Guilford Pharmaceuticals Inc. Methods for treating certain diseases using naaladase inhibitors
US6727224B1 (en) * 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
ATE271886T1 (de) 1999-10-15 2004-08-15 Inst Genetics Llc Hyaluronsäure enthaltende zusammensetzungen zur abgabe osteogener proteine
US20030082233A1 (en) * 2000-12-01 2003-05-01 Lyons Karen M. Method and composition for modulating bone growth
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
WO2002099037A2 (en) * 2001-06-01 2002-12-12 Wyeth Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
TWI267378B (en) * 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
JP3887588B2 (ja) * 2002-08-30 2007-02-28 株式会社リガク Ｘ線回折による応力測定法
DE602004005477T2 (de) * 2003-09-12 2007-12-13 Wyeth Injizierbare feste Calciumphosphat-Stäbe zur Abgabe von osteogenen Proteinen
EP1863518A2 (de) * 2005-03-30 2007-12-12 Wyeth VERFAHREN ZUR STIMULATION DES WAARWACHSTUMS MITTELS VERABREICHUNG VON BMPs
US10961305B2 (en) 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0725798B2 (ja) * 1986-12-15 1995-03-22 東燃料株式会社 ＴＧＦ−β制御糖タンパク質
CA2002011A1 (en) * 1988-11-14 1990-05-14 Anthony F. Purchio Normal human growth regulatory receptor for tgf-beta
US5177197A (en) * 1990-02-27 1993-01-05 Ludwig Institute For Cancer Research Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
DE69133338T2 (de) * 1990-09-26 2004-04-15 Genetics Institute, LLC, Cambridge Bmp-5-derivate
US5229495A (en) * 1991-06-18 1993-07-20 Ludwig Institute For Cancer Research Substantially pure receptor like TGF-β 1 binding molecules and uses thereof
US5280109A (en) * 1992-01-27 1994-01-18 Ludwig Institute For Cancer Research Isolated, large latent complexes of TGF-β2 and TGF-β3, and new binding protein for latent form TGF-β1, TGF-β2 and TGF-β3 LTBP-2

Also Published As

Publication number Publication date
EP0590071B1 (de) 2001-12-19
DE69232309D1 (de) 2002-01-31
US5229495A (en) 1993-07-20
DE69232309T2 (de) 2002-08-14
EP0590071A1 (de) 1994-04-06
DK0590071T3 (da) 2002-04-15
WO1992022319A1 (en) 1992-12-23
AU2261892A (en) 1993-01-12
JPH06508519A (ja) 1994-09-29
CA2111853C (en) 2002-09-17
AU665561B2 (en) 1996-01-11
US5578703A (en) 1996-11-26
EP0590071A4 (en) 1997-01-29
ES2165843T3 (es) 2002-04-01
US5731200A (en) 1998-03-24
DE69232309T4 (de) 2003-02-20
CA2111853A1 (en) 1992-12-23

Similar Documents

Publication Publication Date Title
DE69232309D1 (de) Weitgehend reine rezeptorartige, tgf-beta-1-bindende moleküle und deren verwendungen
BR9910089A (pt) Composições e antìgenos de neisseria meningitidis
CA2251842A1 (en) Small molecule mimetics of erythropoietin
EE03423B1 (et) Kopolümeer-1, selle valmistamismeetod ja seda sisaldavad kompositsioonid
DK0713495T3 (da) Fremgangsmåder til forstærkning af den biologiske aktivitet af chemokiner
DE69638162D1 (de) Bindegewebs wachstumsfaktor (ctgf)
KR910005862A (ko) 신규 친수성 유도체, 진단 또는 치료시 그의 응용 그를 함유하는 진단 또는 치료용 키트 및 면역 시약
ATE89566T1 (de) Molekuele mit mindestens einer peptidsequenz einer oder mehrerer epitopen eines p.falciparum- produzierten proteins in hepatozyten und zusammensetzungen davon.
FI901916A7 (fi) Diagnostinen testipakkaus, alukekoostumus, ja näiden käyttö nukleiinihappojen replikaatioon tai havaitsemiseen
EP1985705A3 (de) Nukleotidsequenzen von Pestivirus-Stämmen, Polypeptide zur Kodierung dieser Sequenzen und deren Verwendung zur Diagnose und Verhinderung von Pestivirus-Infektionen
ATE395364T1 (de) Gegen procalcitonin gerichtete antikörper, ihre herstellung und verwendung
DE68929334D1 (de) Verfahren zumm Assay von Endotoxin-Konzentration
DE69020182D1 (de) Vernetzte Antikörper und Verfahren zu ihrer Herstellung.
DK0877803T3 (da) OB-proteinreceptor og relaterede sammensætninger og fremgangsmåder
ES2148535T3 (es) Valoracion de glucoproteinas.
IL162568A0 (en) fluorescent protein from aequorea coerulscens and uses thereof
DK0486572T3 (da) Forbedringer i granulocyt-makrofag-kolonistimulerende faktorreceptor og derivater deraf
ATE305037T1 (de) Peptide, die fähig sind die sh3-domäne des gap- proteins zu binden, ihre kodierende dns, ihre zubereitung und verwendung
DE59508137D1 (de) Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine
CA2273855A1 (en) Novel feline fc epsilon receptor alpha chain nucleic acid molecules, proteins and uses thereof
ATE152771T1 (de) Methode zur herstellung und prüfung von verwendbaren peptiden
EA200000522A1 (ru) 5-htагонисты
DE59003113D1 (de) Bindemittelkombinationen, ein Verfahren zu ihrer Herstellung und ihre Verwendung.
AU4136797A (en) Novel semaphorin gene: semaphorin y
ATE281519T1 (de) Klonierung und rekombinante herstellung des crf- rezeptors (crf=corticotropin ausloese faktor)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee